Radioligand therapy is an innovative approach to treating certain types of cancer by delivering radiation to specifically targeted cancer cells, with a minimal effect on healthy cells.
Genetic mutations in the BRCA1 and BRCA2 genes are associated with a significant risk of developing breast cancer, but many people who may carry these mutations cannot access genetic testing.
As the incidence of cancer increases, healthcare systems must find effective and sustainable ways to care for all cancer patients – and radiotherapy is a key part of this.
Despite advances in research and treatment in recent years, sarcoma patients report some of the poorest experiences of care among people with cancer.
All.Can is an international initiative working to improve efficiency in cancer care by focusing on what matters to patients.